Bleeding Risk with Dual Antiplatelet Therapy and Potential Influence of Methamphetamine Use

Baseline Bleeding Risk of Dual Antiplatelet Therapy

Dual antiplatelet therapy (aspirin + a P2Y12 inhibitor) raises the risk of major bleeding 2‑ to 3‑fold compared with aspirin alone, with an absolute risk increase of 0.6 %–2.0 % in patients with acute coronary syndromes. American Heart Association recommendation. 1
The relative bleeding risk is higher when prasugrel or ticagrelor are used instead of clopidogrel in combination with aspirin. American Society of Anesthesiologists guidance. 2

Concomitant use of anticoagulants, systemic steroids, or non‑steroidal anti‑inflammatory drugs consistently predicts gastrointestinal bleeding in patients receiving dual antiplatelet therapy. American Heart Association data. 4

Acute hypertension and tachycardia induced by methamphetamine could exacerbate bleeding from existing mucosal injuries or vascular lesions that are already prone to hemorrhage due to antiplatelet effects. American Heart Association observation. 4
Methamphetamine‑related vasospasm and endothelial injury may create new sites vulnerable to bleeding when platelet function is pharmacologically suppressed. American Society of Anesthesiologists insight. 2
Poor medication adherence and erratic health‑care engagement associated with methamphetamine use may lead to missed antiplatelet doses followed by “catch‑up” dosing, potentially destabilizing hemostasis. American Heart Association report. 4
Increased risk‑taking behavior in methamphetamine users raises the likelihood of traumatic injuries while on antiplatelet therapy, adding an external source of bleeding. American Heart Association report. 4

Assess all patients on dual antiplatelet therapy for established bleeding risk factors (prior GI bleed, age > 65 years, concurrent anticoagulants, NSAIDs, steroids) before considering any modification of therapy. American Heart Association recommendation. 4
Prescribe a proton‑pump inhibitor for gastrointestinal prophylaxis in patients who have additional bleeding risk factors while on dual antiplatelet therapy. American Heart Association guidance. 4
Balance bleeding risk against thrombotic risk according to the specific indication for dual antiplatelet therapy (e.g., recent stent placement, acute coronary syndrome timing, secondary stroke prevention). American Heart Association and American Society of Anesthesiologists consensus. [1][2]